Even though drugs targeting tyrosine kinase activity (e.g., HER2, FGFR, EGFR, VEGFR2), can prolong survival by inducing cancer regression, the lack of selectivity to a single target and/or development of drug resistance remains a problem. This evidence concerns the gene KDR and cancer.